Issue
Copyright (c) 2023 Xin Li, Lijun Li
This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License.
The undersigned hereby assign all rights, included but not limited to copyright, for this manuscript to CMB Association upon its submission for consideration to publication on Cellular and Molecular Biology. The rights assigned include, but are not limited to, the sole and exclusive rights to license, sell, subsequently assign, derive, distribute, display and reproduce this manuscript, in whole or in part, in any format, electronic or otherwise, including those in existence at the time this agreement was signed. The authors hereby warrant that they have not granted or assigned, and shall not grant or assign, the aforementioned rights to any other person, firm, organization, or other entity. All rights are automatically restored to authors if this manuscript is not accepted for publication.Meta-analysis of the effect of FLT3 inhibitor maintenance therapy on survival and chronic graft-versus-host disease in allogeneic hematopoietic stem cell transplantation for malignant hematologic disease
Corresponding Author(s) : Lijun Li
Cellular and Molecular Biology,
Vol. 69 No. 10: Issue 10
Abstract
This study aimed to investigate the effect of FLT3 inhibitor maintenance therapy on survival and chronic graft-versus-host diseases (cGVHD) in allogeneic hematopoietic stem cell transplantation (allo-HSCT) for malignant hematologic disease (MHD) by meta-analysis. For this purpose, Pubmed, Web of Science, Embase, and The Cochrane Library were searched for studies published up to April 2023. The search term was set as "FLT3 inhibitor". "allogeneic hematopoietic stem cell transplantation"; "malignant hematologic disease"; "chronic graft-versus-host disease". The literature was screened according to the inclusion and exclusion criteria, and then the data were extracted and analyzed by Revman5.3 software. Results showed that 9 eligible studies involving 964 patients were obtained. The relapse-free survival (RFS) of patients after treatment was analyzed by comprehensive model, odds ratio=3.28, 95% confidence interval (CI) = 1.76-6.11, Z=3.75, P=0.0002; Comprehensive model analysis of overall survival (OS), odds ratio=2.85, 95% CI= 2.12-3.83, Z=6.95, P <0.00001; Comprehensive model analysis of cGVHD, odds ratio=1.06, 95%CI = 0.37-2.98, Z=0.11, P=0.92. It was concluded that FLT3 inhibitor maintenance therapy could improve the RFS and OS of MHD patients treated with allo-HSCT but did not markedly affect the occurrence of cGVHD.
Keywords
Download Citation
Endnote/Zotero/Mendeley (RIS)BibTeX
